Mesoblast Ltd MESO.OQ, MESO.O is expected to report resultson February 27 for the period ending September 30 2024
The Melbourne Victoria-based company is expected to report revenue of $1.493 million, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Mesoblast Ltd is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mesoblast Ltd is $27.00, above its last closing price of $16.23.
This summary was machine generated February 25 at 11:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。